I heard a justification of all this at the EGM by phil daffis, made me confident of their plan, and with a guy who was VP of marketing at Cochlear I reckon he knows more than I do...don't forget they have noted a milestone of a commercial product in the dementia industry back end of 2017. Revenue is thus expected, they have clearly stated the milestones they aim to achieve for commercialisation, I read an annual report of another company this week which was scarce on timing for their commercial product. I think a point will come where the market will click that EPT isn't that far away from being commercial with a product .
- Forums
- ASX - By Stock
- MNQ
- Ann: Change of Company Name-MNQ.AX
Ann: Change of Company Name-MNQ.AX, page-34
-
-
- There are more pages in this discussion • 12 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)